Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Table 1

Patient characteristics.

Covariates
Number	46
Age (years, median, IQR)	72 (67–75)
Body mass index (kg/m^2, median, IQR)	23.0 (21.0–24.8)
Initial PSA (ng/mL, median, IQR)	113.9 (15.5–653.1)
Gleason Grade (number, %)
≤2	0 (0)
≥3	43 (93.5)
Unknown	3 (6.5)
Definitive treatment for prostate (number, %)	11 (23.9)
Time to CRPC after initial diagnosis (months, median, IQR)	14.5 (9.0–21.3)
The number of the administration of ARTs (number, median, %)	1 (1-2)
The number of cycles of DOC (number, median, IQR)	8 (4–16.5)
Metastasis (number, %)
Bone	42 (91.3)
Visceral	10 (21.7)
Lactate dehydrogenase (U/L, median, IQR)	260 (222–322)
Alkaline phosphatase (U/L, median, IQR)	297 (243–524)
Hemoglobin (g/dL, median, IQR)	12.1 (10.9–12.8)

IQR = interquartile range; PSA = prostate-specific antigen; CRPC = castration-resistant prostate cancer; ART = androgen receptor-axis-targeted agent; DOC = docetaxel.